Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$24.2 million.

  • Taysha Gene Therapies' Cash from Operations fell 1180.2% to -$24.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.7 million, marking a year-over-year decrease of 713.87%. This contributed to the annual value of -$81.2 million for FY2024, which is 1123.97% down from last year.
  • Latest data reveals that Taysha Gene Therapies reported Cash from Operations of -$24.2 million as of Q3 2025, which was down 1180.2% from -$20.2 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Cash from Operations ranged from a high of $14.7 million in Q4 2022 and a low of -$40.9 million during Q1 2022
  • Moreover, its 4-year median value for Cash from Operations was -$20.2 million (2023), whereas its average is -$20.6 million.
  • The largest annual percentage gain for Taysha Gene Therapies' Cash from Operations in the last 5 years was 5069.49% (2023), contrasted with its biggest fall of 20955.0% (2023).
  • Quarter analysis of 4 years shows Taysha Gene Therapies' Cash from Operations stood at $14.7 million in 2022, then plummeted by 209.55% to -$16.1 million in 2023, then fell by 13.59% to -$18.3 million in 2024, then tumbled by 32.0% to -$24.2 million in 2025.
  • Its Cash from Operations stands at -$24.2 million for Q3 2025, versus -$20.2 million for Q2 2025 and -$22.0 million for Q1 2025.